April 5, 2022, Vol 327, No. 13, Pages 1209-1300
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19A Randomized Clinical Trial
Anil Gupta, MD; Yaneicy Gonzalez-Rojas, MD; Erick Juarez, MD; et al.
free access has active quiz
JAMA. 2022;327(13):1236-1246. doi:10.1001/jama.2022.2832
This randomized clinical trial compares the efficacy and adverse events of sotrovimab vs placebo in preventing progression of mild to moderate COVID-19 to severe disease.